An observational study in Neuropathic Pain, Spinal Cord Injuries and Central Neuropathic Pain, sponsored by Institut Guttmann. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-07-31.
Sponsored by Institut Guttmann · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Neuralgia with a site in Spain — 3 open to participants now, 4 under way, 1 of them phase 3. Neuralgia · Spain.
Among the 32 studies in Neuralgia with a site in Spain, this one is one of 3 that started in 2023, is one of 4 observational ones, and was the 28th registered.
1,103 studies on the registry are indexed under Neuralgia; 243 are open to participants now.
Browse Neuralgia studies →3 of the 32 studies in Neuralgia with a site in Spain are open now. Recruiting first, the newest first:
Bernardino Clavo, MD, PhD · Sites in Spain
Ages 18–100
Instituto de investigación e innovación biomédica de Cádiz · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 155 Neuralgia studies recruiting now, 79 (51%) set no upper age limit and 44 (28%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 12 · Phase 3 5 · Phase 4 4
First in 2005; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 58 is below the median of 102 across 232 observational studies indexed under Neuralgia.
Median enrollment 108 across the 28 interventional studies, 315 across the 4 observational. Of the 23 that completed or were terminated, 7 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 32 have an industry lead sponsor. The 10 most frequent:
Institut Guttmann is the lead sponsor of 19 studies on the registry; 6 are open to participants now.
Institut Guttmann has 2 studies filed under Neuralgia — fewer than ten, so there is no comparison to draw.
1 of the studies in Neuralgia with a site in Spain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04299893Phase 3Bernardino Clavo, MD, PhDOzone Therapy in Chemotherapy-induced Peripheral Neuropathy: RCT (O3NPIQ) | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 32 studies in Neuralgia with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to develop a machine learning model to predict the outcome of a transcranial direct current stimulation (tDCS) treatment in patients suffering from neuropathic pain derived from a spinal cord injury. The main question it aims to answer is:
Participants will:
This project aims to develop an artificial intelligence model to predict the response to a neuromodulation treatment (transcranial Direct Current Stimulation, tDCS) for neuropathic pain (NP) following spinal cord injury (SCI), based on electroencephalographic (EEG) signals and clinical assessments. The project consists of two stages:
Stage 1 involves an open trial where participants with SCI and NP will receive neuromodulation treatment at our center, with data collected before and after treatment.
Pre-Treatment Evaluation:
Neuromodulation Treatment:
Post-Treatment Evaluation:
As part of the intervention, participants will undergo EEG recording to study the brain's bioelectrical activity non-invasively. Active surface electrodes with electrode gel will be used to enhance skin conductivity. EEG recordings will be conducted at rest, with participants looking at a blank wall in a soundproof room, for 5 minutes with eyes open and 5 minutes with eyes closed.
Stage 2 involves developing a predictive model to classify patients based on their response to the neuromodulation treatment. The model will use metrics derived from pre-treatment EEG recordings and clinical assessments conducted before and after the treatment, with the goal of predicting which patients will respond favorably to tDCS.
EEG preprocessing will be performed by means of the Python programming language, using a custom-made preprocessing pipeline based on the MNE-Python library including: selective outlier channel and segment elimination, frequency filters, supervised auto-labeled independent component analysis for the elimination of muscular and ocular activity, and detection of bridged electrodes.
The EEG recordings will be analyzed using metrics derived from the frequency, complexity and connectivity of the EEG signal. These metrics were selected due to their demonstrated potential in related publications, which highlight the capability of these features to capture differences between groups, either between treatment responders and non-responders, or between healthy subjects and those suffering from NP, among others. Based on these EEG features and other features derived from patient questionnaires, a feature selection process based on metric independence and relevance in previous literature will be carried out in order to maximize model generalizability.
A machine learning (ML) model, with the main candidate model being a support vector machine (SVM), will be used in order to classify between responders and non-responders. The model will be validated by means of k-fold cross-validation. Given satisfactory results, an undersampling of EEG channels (adhering to typical 10:20 setups) will be used to evaluate whether an EEG with less electrodes can yield similar predictive results, thus reducing the need for EEG systems with a high electrode count.
Patients with spinal cord injury (SCI) suffering from neuropathic pain (NP).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects suffering from NP pain after an SCI. Will receive a tDCS treatment.
Device: transcranial Direct Current Stimulation · Diagnostic Test: Electroencephalography
The treatment follows an approved neuromodulation protocol at our center (approved on Nov. 4 2021, valid until Nov. 4 2024). tDCS will be administered with a battery-powered DC stimulator (Sooma tDCS, Helsinki, Finland), using saline-saturated circular electrodes with a diameter of 6 cm². The anode will be positioned over C3 to stimulate the primary motor cortex (M1), and the cathode over the contralateral supraorbital area (FP2). For asymmetric pain, stimulation targets the M1 contralateral to the more painful side, and for symmetric pain, the dominant hemisphere (C3) is stimulated. The maximum current is 2 mA (current density: 0.06 mA/cm²). Each session lasts 30 minutes, conducted daily for two weeks (Monday to Friday), totaling 10 sessions. All stimulation parameters adhere to general safety guidelines for transcranial electrical stimulation (Bikson et al., 2016).
Also known as: tDCS, tCS
64-channel active-electrode EEG with impedances kept \~5KOhm
Also known as: EEG
Patient Improvement as assessed by a composite score
Composite Score Breakdown: Neuropathic Pain Symptom Inventory (NPSI) Items: * Constant pain intensity: Questions 1, 2, 3, 11, 12 (sum) * Constant pain persistence/frequency: Question 4 * Pain crisis intensity: Questions 5, 6 (sum) * Pain crisis frequency: Question 7 * Allodynia: Questions 8, 9, 10 (sum) Criteria: * Numerical NPSI items are only used where pre-treatment pain ratings are 4/10 or higher. * Responder: Any NPSI item shows a 50% or larger reduction. Brief Pain Inventory (BPI) Items: * Pain Interference: Questions 3a - 3g (average) Criteria: * Responder: 30% improvement or more. Summary: A subject is considered a responder if BOTH of these conditions are met: 1. Improvement of 50% or more in pain intensity or frequency (NPSI). 2. Improvement of 30% or more in pain interference (BPI).
Time frame: After tDCS treatment (compared to score before tDCS treatment)
Started Oct 2023 (actual). Primary completion is estimated for Nov 2025, 25 months after the start.
Of 77 non-industry observational studies under Neuralgia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 51. This study's planned 25 months is above that.
Counting every sponsor, half of 88 studies reached it within 18 months; a quarter within 12 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut Guttmann